<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487303</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041193</org_study_id>
    <nct_id>NCT02487303</nct_id>
  </id_info>
  <brief_title>Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery</brief_title>
  <official_title>Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare IV (intravenous) versus oral (PO) acetaminophen for postoperative
      pain after scheduled, elective Cesarean delivery. All patients will receive a standardized
      spinal anesthetic for operative anesthesia and will be randomized into one of three groups:
      (group 1) 1 gram IV acetaminophen every 8 hours for three doses, (group 2) 1 gram oral
      acetaminophen every 8 hours for three doses, or (group 3) no acetaminophen. This will be a
      randomized, open label study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare IV versus PO acetaminophen for postoperative pain in parturients
      after scheduled, elective Cesarean delivery. It is designed as a randomized, open label,
      controlled trial. All patients will receive a standardized spinal anesthetic for operative
      anesthesia and will be randomized into one of three groups: (group 1) 1 gram IV acetaminophen
      every 8 hours for three by a computer generated list.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2015</start_date>
  <completion_date type="Actual">July 27, 2017</completion_date>
  <primary_completion_date type="Actual">July 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Postoperative Opiate Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Cumulative opiate consumption (IV morphine equivalents)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Opiate Rescue</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to first opiate pain medicine requested by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual Analog Scale)</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual Analog Scale (VAS) pain assessment with ambulation. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; For pain intensity, the scale is most commonly anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100 [100‐mm scale]) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Discharge</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Time patient meets discharge criteria will be recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Acetaminophen Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen Oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No acetaminophen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(group 3) no acetaminophen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen Intravenous</intervention_name>
    <description>IV 1 gram f3 doses over 24 hours</description>
    <arm_group_label>Acetaminophen Intravenous</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen Oral</intervention_name>
    <description>Oral 1 gram 3 doses over 24 hours</description>
    <arm_group_label>Acetaminophen Oral</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parturients 18 years

          -  Elective Cesarean delivery

          -  Spinal anesthesia

          -  Able to consent to the study and participate in the follow-up.

        Exclusion Criteria:

          -  Weight under 50 kgs

          -  Allergy to acetaminophen

          -  General anesthesia

          -  Urgent or emergent cases

          -  Bleeding diathesis or other coagulopathy

          -  G6PD deficiency

          -  Liver disease

          -  Substance abuse or dependence

          -  HELLP syndrome

          -  Thrombocytopenia or platelet dysfunction

          -  History or active gastrointestinal bleeding

          -  Acute kidney injury or chronic renal insufficiency

          -  Contraindication/refusal to spinal anesthesia

          -  Chronic pain

          -  Chronic narcotic use

          -  Illicit drug use

          -  Allergy to any study related medications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Macario A, Royal MA. A literature review of randomized clinical trials of intravenous acetaminophen (paracetamol) for acute postoperative pain. Pain Pract. 2011 May-Jun;11(3):290-6. doi: 10.1111/j.1533-2500.2010.00426.x. Epub 2010 Nov 28. Review.</citation>
    <PMID>21114616</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith HS. Perioperative intravenous acetaminophen and NSAIDs. Pain Med. 2011 Jun;12(6):961-81. doi: 10.1111/j.1526-4637.2011.01141.x. Epub 2011 May 31. Review.</citation>
    <PMID>21627768</PMID>
  </results_reference>
  <results_reference>
    <citation>Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010 Dec;32(14):2348-69. doi: 10.1016/j.clinthera.2010.12.011.</citation>
    <PMID>21353105</PMID>
  </results_reference>
  <results_reference>
    <citation>Singla NK, Parulan C, Samson R, Hutchinson J, Bushnell R, Beja EG, Ang R, Royal MA. Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. Pain Pract. 2012 Sep;12(7):523-32. doi: 10.1111/j.1533-2500.2012.00556.x. Epub 2012 Apr 24.</citation>
    <PMID>22524979</PMID>
  </results_reference>
  <results_reference>
    <citation>Fenlon S, Collyer J, Giles J, Bidd H, Lees M, Nicholson J, Dulai R, Hankins M, Edelman N. Oral vs intravenous paracetamol for lower third molar extractions under general anaesthesia: is oral administration inferior? Br J Anaesth. 2013 Mar;110(3):432-7. doi: 10.1093/bja/aes387. Epub 2012 Dec 6.</citation>
    <PMID>23220855</PMID>
  </results_reference>
  <results_reference>
    <citation>Alhashemi JA, Alotaibi QA, Mashaat MS, Kaid TM, Mujallid RH, Kaki AM. Intravenous acetaminophen vs oral ibuprofen in combination with morphine PCIA after Cesarean delivery. Can J Anaesth. 2006 Dec;53(12):1200-6.</citation>
    <PMID>17142654</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong JY, Carvalho B, Riley ET. Intrathecal morphine 100 and 200 μg for post-cesarean delivery analgesia: a trade-off between analgesic efficacy and side effects. Int J Obstet Anesth. 2013 Jan;22(1):36-41. doi: 10.1016/j.ijoa.2012.09.006. Epub 2012 Nov 15.</citation>
    <PMID>23159009</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh SI, Rehou S, Marmai KL, Jones PM. The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial. Anesth Analg. 2013 Sep;117(3):677-85. doi: 10.1213/ANE.0b013e31829cfd21. Epub 2013 Aug 6.</citation>
    <PMID>23921652</PMID>
  </results_reference>
  <results_reference>
    <citation>Beatty NC, Arendt KW, Niesen AD, Wittwer ED, Jacob AK. Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine. J Clin Anesth. 2013 Aug;25(5):379-383. doi: 10.1016/j.jclinane.2013.01.014. Epub 2013 Aug 17.</citation>
    <PMID>23965210</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>July 30, 2018</results_first_submitted>
  <results_first_submitted_qc>November 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Analgesia, Obstetrical</keyword>
  <keyword>Cesarean Section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02487303/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen Intravenous</title>
          <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses
Acetaminophen Intravenous: IV 1 gram f3 doses over 24 hours</description>
        </group>
        <group group_id="P2">
          <title>Acetaminophen Oral</title>
          <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses
Acetaminophen Oral: Oral 1 gram 3 doses over 24 hours</description>
        </group>
        <group group_id="P3">
          <title>No Acetaminophen</title>
          <description>(group 3) no acetaminophen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen Intravenous</title>
          <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses
Acetaminophen Intravenous: IV 1 gram f3 doses over 24 hours</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen Oral</title>
          <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses
Acetaminophen Oral: Oral 1 gram 3 doses over 24 hours</description>
        </group>
        <group group_id="B3">
          <title>No Acetaminophen</title>
          <description>(group 3) no acetaminophen</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" lower_limit="19" upper_limit="44"/>
                    <measurement group_id="B2" value="30.5" lower_limit="21" upper_limit="43"/>
                    <measurement group_id="B3" value="31.2" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B4" value="30.1" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Postoperative Opiate Consumption</title>
        <description>Cumulative opiate consumption (IV morphine equivalents)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen Intravenous</title>
            <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses
Acetaminophen Intravenous: IV 1 gram f3 doses over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen Oral</title>
            <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses
Acetaminophen Oral: Oral 1 gram 3 doses over 24 hours</description>
          </group>
          <group group_id="O3">
            <title>No Acetaminophen</title>
            <description>(group 3) no acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Postoperative Opiate Consumption</title>
          <description>Cumulative opiate consumption (IV morphine equivalents)</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0" upper_limit="17.5"/>
                    <measurement group_id="O3" value="5.7" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opiate Rescue</title>
        <description>Time to first opiate pain medicine requested by patient</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen Intravenous</title>
            <description>1 gram IV acetaminophen every 8 hours for three doses</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen Oral</title>
            <description>1 gram oral acetaminophen every 8 hours for three doses</description>
          </group>
          <group group_id="O3">
            <title>No Acetaminophen</title>
            <description>No acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opiate Rescue</title>
          <description>Time to first opiate pain medicine requested by patient</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="8.5"/>
                    <measurement group_id="O2" value="24.0" spread="26.3"/>
                    <measurement group_id="O3" value="21.3" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS (Visual Analog Scale)</title>
        <description>Visual Analog Scale (VAS) pain assessment with ambulation. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; For pain intensity, the scale is most commonly anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100 [100‐mm scale]) .</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen Intravenous</title>
            <description>1 gram IV acetaminophen every 8 hours for three doses</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen Oral</title>
            <description>1 gram oral acetaminophen every 8 hours for three doses</description>
          </group>
          <group group_id="O3">
            <title>No Acetaminophen</title>
            <description>No acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>VAS (Visual Analog Scale)</title>
          <description>Visual Analog Scale (VAS) pain assessment with ambulation. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; For pain intensity, the scale is most commonly anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100 [100‐mm scale]) .</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="3.23"/>
                    <measurement group_id="O2" value="44.3" spread="3.28"/>
                    <measurement group_id="O3" value="50.8" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Discharge</title>
        <description>Time patient meets discharge criteria will be recorded</description>
        <time_frame>24 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen Intravenous</title>
            <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses
Acetaminophen Intravenous: IV 1 gram f3 doses over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen Oral</title>
            <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses
Acetaminophen Oral: Oral 1 gram 3 doses over 24 hours</description>
          </group>
          <group group_id="O3">
            <title>No Acetaminophen</title>
            <description>(group 3) no acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Time Discharge</title>
          <description>Time patient meets discharge criteria will be recorded</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="13.7"/>
                    <measurement group_id="O2" value="48.6" spread="11.3"/>
                    <measurement group_id="O3" value="50.5" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The timeframe for adverse event data was collected up to 48 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen Intravenous</title>
          <description>(group 1) 1 gram IV acetaminophen every 8 hours for three doses
Acetaminophen Intravenous: IV 1 gram f3 doses over 24 hours</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen Oral</title>
          <description>(group 2) 1 gram oral acetaminophen every 8 hours for three doses
Acetaminophen Oral: Oral 1 gram 3 doses over 24 hours</description>
        </group>
        <group group_id="E3">
          <title>No Acetaminophen</title>
          <description>(group 3) no acetaminophen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sylvia Wilson</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>8437921414</phone>
      <email>wilsosh@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

